Group items tagged

This Funding Opportunity Announcement (FOA) solicits research projects that study the mechanisms of oral immune system plasticity relevant to chronic HIV infection and oral coinfections.In this context, we encourage studies on reversal of immune activation, residual inflammation, immune reconstitution inflammatory syndrome (IRIS), and microbial and by-product translocation.These conditions occur in persons chronically infected with HIV who are treated with combination antiretroviral therapy (cART) and who also experience oral opportunistic infections.The ultimate goals of this FOA are: 1) to gain knowledge regarding the pathogenesis and persistence of these oral conditions; and 2) to guide the development of novel oral immune modulatory therapies that will aid in re-building the oral immune system to reverse these diseases, mitigate their progression, prevent their occurrence, and eliminate persistence of residual HIV and other oral pathogens in reservoirs.

This Funding Opportunity Announcement (FOA) solicits research projects that study the mechanisms of oral immune system plasticity relevant to chronic HIV infection and oral coinfections. In this context, we encourage studies on reversal of immune activation, residual inflammation, immune reconstitution inflammatory syndrome (IRIS), and microbial and by-product translocation. These conditions occur in persons chronically infected with HIV who are treated with combination antiretroviral therapy (cART) and who also experience oral opportunistic infections. The ultimate goals of this FOA are: 1) to gain knowledge regarding the pathogenesis and persistence of these oral conditions; and 2) to guide the development of novel oral immune modulatory therapies that will aid in re-building the oral immune system to reverse these diseases, mitigate their progression, prevent their occurrence, and eliminate persistence of residual HIV and other oral pathogens in reservoirs.

This Funding Opportunity Announcement (FOA) solicits research projects that study the mechanisms of oral immune system plasticity relevant to chronic HIV infection and oral coinfections.  In this context, we encourage studies on reversal of immune activation, residual inflammation, immune reconstitution inflammatory syndrome (IRIS), and microbial and by-product translocation.  These conditions occur in persons chronically infected with HIV who are treated with combination antiretroviral therapy (cART) and who also experience oral opportunistic infections.  The ultimate goals of this FOA are: 1) to gain knowledge regarding the pathogenesis and persistence of these oral conditions; and 2) to guide the development of novel oral immune modulatory therapies that will aid in re-building the oral immune system to reverse these diseases, mitigate their progression, prevent their occurrence, and eliminate persistence of residual HIV and other oral pathogens in reservoirs.

This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial research with a focus on behavioral and social sciences, and genetic and genomic research. The intent of this program is to provide mid-career or senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established dental, oral, and craniofacial research investigators who seek training with investigators from another field, in order to enrich their existing dental, oral and craniofacial research program; and (b) established investigators in other fields who seek training with dental, oral and craniofacial research investigators in order to facilitate the introduction of dental, oral and craniofacial research into an existing research program.

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

The goal of this Funding Opportunity Announcement (FOA) is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens.  These studies will advance our understanding of the immunologic, pathogenic, molecular and cellular mechanisms important for eliminating latently persistent, reactivation competent HIV and other opportunistic pathogens from residual oral reservoirs.  Specifically, this FOA encourages studies on: 1) purging and abolishing these pathogens after using Highly Active Anti-Retroviral Therapy (HAART) to induce cytopathic killing and immunoclearance; or 2) developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

The goal of this Funding Opportunity Announcement (FOA) is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens.These studies will advance our understanding of the immunologic, pathogenic, molecular and cellular mechanisms important for eliminating latently persistent, reactivation competent HIV and other opportunistic pathogens from residual oral reservoirs.Specifically, this FOA encourages studies on: 1) purging and abolishing these pathogens after using Highly Active Anti-Retroviral Therapy (HAART) to induce cytopathic killing and immunoclearance; or 2) developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/ developmental research on biologic factors that mediate the differences in prevalence and severity of Dental, Oral, and Craniofacial (DOC)-related diseases and conditions in oral health disparities populations. It is long recognized that certain racial and ethnic populations suffer an increased burden of DOC diseases and conditions, such as oral/oropharyngeal cancers, early childhood caries (ECC), dental caries, and periodontitis. For each of these diseases, substantial racial and ethnic differences exist in prevalence, severity, persistence and/or disease progression. Biologic factors are believed to play a role in oral health disparities in addition to behavioral, social, and environmental factors. Because critical scientific gaps remain in our understanding of underlying biologic mechanisms that could contribute to these differences, it is difficult to develop targeted therapeutic regimens for those in greatest need.

The purpose of this Funding Opportunity Announcement (FOA) is to support research aimed at understanding the biological and physiological effects of aerosol mixtures produced by electronic cigarettes (ECs) on cells, tissues and organs of the oral cavity including oral and periodontal epithelia, gingiva, salivary glands, and tooth. This FOA will also support research on elucidation of the effects of ECs on oral microbiome.  Research supported by this FOA would provide essential and necessary information on the biological effects of ECs that would in turn lead to evidence based foundational information for health policy decisions.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate collaborative research to understand the biological mechanisms of aging in dental, oral, and craniofacial (DOC) tissues, as they relate to parallel processes in other tissues and organs. The areas of emphasis under this FOA include inflammation, tissue healing and regeneration, and epigenetic regulation. The overarching long-term goal of this effort is to improve oral health in older adults by addressing knowledge gaps in our understanding of the basic biology of age-associated changes in health and disease states of DOC tissues. Also listed under R01

Candidates must indicate an interest in schizophrenia research and, if possible, provide evidence of continuing and future involvement and activity in the field.  Individuals must be graduate students, residents, fellows or new/young faculty members that have completed their last training in the last 5 years.  Candidates who are members of an ethnic minority group or from a low income country, underrepresented in biomedical science areas, are strongly encouraged to apply.  Awardees are required to submit a poster or oral presentation abstract.  Awardees will also participate in the meeting as rapporteurs of oral sessions and their reports will be edited into a published summary of the congress after it occurs.  Application deadline is Monday, 21 October 2013.  The travel award recipients will be announced on Friday, 22 November.

The training of a new generation of psychiatric academicians is a major objective of the Society of Biological Psychiatry.  Participation in professional meetings, where new information is exchanged and contacts are made, can have a critical impact on the career of a developing clinician-scientist. In recognition of the importance of academic exchange, the Society of Biological Psychiatry (SOBP) annually selects distinguished junior scientists to be a part of our Travel Fellowship Award program. Each travel fellowship award includes: $1,500 to help defray the travel and living cost to attend the 2014 annual meeting Waived registration to attend the 2014 meeting Waived registration to attend the 2015 and 2016 annual meeting (no financial award) An SOBP member mentor assigned to you during the meeting Opportunity to present a poster or oral abstract without an SOBP member sponsor Recognition events in honor of the Travel Fellowship Award recipeints To receive the travel award, applicants are expected to attend the entire meeting, be present for the recognition events, submit an abstract for a poster or oral presentation, and participate in the mentor/mentee program for young investigators.  These awards are supported by the Society of Biological Psychiatry and Elsevier, publisher of the Society's journal, Biological Psychiatry.

The goal of this reissued Funding Opportunity Announcement (FOA) is to expand understanding of age-related changes that occur in immune function during the aging process that influence responses to pathogens and/or vaccines, as well as oral and craniofacial health. Human studies are required, and inclusion of relevant animal studies is permitted for mechanistic understanding. This FOA solicits applications that will determine the mechanisms required for induction and maintenance of protective immunity in the elderly in response to infections and/or vaccinations, including the effects of chronic inflammation on those responses, and applications that will assess changes in immune processes in dental, oral and craniofacial tissues in the elderly.

The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.

This Funding Opportunity Announcement (FOA) seeks to stimulate innovative research that will increase our understanding of the role that uncultivable bacterial species play in the microbial ecology of the human oral microbiota during states of health and disease. The effective integration of current technologies and the development of new tools and innovative methods are especially encouraged.  Due to the wide spectrum of possible experimental approaches and the multidisciplinary tools that will be required to study this unique microbial population, this FOA is designed specifically to encourage team science that will leverage innovation, broad expertise and multiple technological platforms to answer hypothesis-driven questions regarding these bacteria.  Consistent with this approach, the use of a multiple Program Directors/Principal Investigators (PDs/PIs) model is encouraged that will recruit complementary and collaborative research teams to conduct these studies.